Edition:
India

Radius Health Inc (RDUS.OQ)

RDUS.OQ on NASDAQ Stock Exchange Global Market

29.98USD
15 Dec 2017
Change (% chg)

$1.32 (+4.61%)
Prev Close
$28.66
Open
$27.47
Day's High
$30.42
Day's Low
$27.22
Volume
624,133
Avg. Vol
323,251
52-wk High
$49.15
52-wk Low
$24.68

Chart for

About

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosi... (more)

Overall

Beta: 1.31
Market Cap(Mil.): $1,686.22
Shares Outstanding(Mil.): 43.50
Dividend: --
Yield (%): --

Financials

BRIEF-Radius Health Expects CHMP To Issue Opinion Regarding Marketing Authorization Application Of Abaloparatide-Sc during H1 2018

* RADIUS HEALTH ANNOUNCES THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) WILL ISSUE A THIRD DAY-180 LIST OF OUTSTANDING ISSUES IN ITS REGULATORY REVIEW OF ABALOPARATIDE-SC, A BONE BUILDING AGENT FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURE

15 Dec 2017

BRIEF-Point72 Asset Management Reports 5.1 Percent Passive Stake In Radius Health

* POINT72 ASSET MANAGEMENT, L.P REPORTS 5.1 PERCENT PASSIVE STAKE IN RADIUS HEALTH INC AS OF NOVEMBER 24, 2017 - SEC FILING‍​ Source text: (http://bit.ly/2iXLIQS) Further company coverage:

28 Nov 2017

BRIEF-Radius Health reports Q3 loss per share $1.31

* Radius Health Inc reports third quarter 2017 financial and operating results and provides business update

03 Nov 2017

BRIEF-Radius Health receives FDA fast track designation for elacestrant

* Radius health receives fda fast track designation for elacestrant (rad1901)

18 Oct 2017

BRIEF-Radius Health initiates Phase 1 clinical trial of RAD140 for treatment of hormone receptor positive breast cancer

* Radius Health initiates Phase 1 clinical trial of RAD140 for the treatment of hormone receptor positive breast cancer

29 Sep 2017

BRIEF-Radius Health prices $300 mln of 3 pct convertible senior notes due 2024

* Radius Health announces pricing of $300 million of 3.00 percent convertible senior notes due 2024

09 Aug 2017

BRIEF-Radius Health announces proposed public offering of $300 million of convertible senior notes due 2024

* Radius Health - to use net proceeds to support U.S. commercial launch of Tymlos injection, development of its life cycle management activities​ Source text for Eikon: Further company coverage:

08 Aug 2017

BRIEF-Radius Health reports Q2 loss per share $1.58

* Radius Health reports second quarter 2017 financial and operating results and provides business update

04 Aug 2017

BRIEF-Radius Health appoints Jesper Høiland as president and CEO

* Radius Health appoints Jesper Høiland as president and chief executive officer to lead the next stage of growth and value creation as a fully integrated commercial biotech company

17 Jul 2017

BRIEF-Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan

* Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan

13 Jul 2017

Earnings vs. Estimates